SCHEMBL4515967

SCHEMBL4515967

Clc1ccccc1-c1cscn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.47
IDO1 P14902 4/20 0.46
TDO2 P48775 2/20 0.45
ATP4A P20648 2/20 0.41
ATP4B P51164 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
NPC1 O15118 2/20 0.41
TP53 P04637 2/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
METAP2 P50579 2/20 0.41
METAP1 P53582 2/20 0.41
KDM4E B2RXH2 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
CYP2D6 P10635 1/20 0.41
TSHR P16473 1/20 0.41
CYP2C19 P33261 1/20 0.41
FKBP1A P62942 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28360058 0.82 SCN9A (0.37) CYP19A1IDO1TDO2TDP1NPC1
SCHEMBL4518539 0.78 LMNA (0.53) IDO1TDO2TDP1NPC1TP53
SCHEMBL10151029 0.78 METAP2 (0.39) CYP19A1IDO1TDO2TDP1NPC1
SCHEMBL4533718 0.77 CASP6 (0.45) CYP19A1IDO1TDO2TDP1NPC1
SCHEMBL7777776 0.77 IDO1 (0.48) IDO1TDO2TDP1NPC1TP53
SCHEMBL23249848 0.77 IDO1 (0.39) IDO1TDO2KDM4ESCN9AALDH1A1
SCHEMBL10151023 0.76 MPL (0.50) IDO1TDO2TDP1NPC1TP53
SCHEMBL4533675 0.76 METAP2 (0.46) IDO1TDO2ATP4AATP4BTDP1
SCHEMBL466425 0.76 IDO1 (0.46) IDO1TDO2TDP1NPC1TP53
SCHEMBL11815358 0.76 IDO1 (0.46) IDO1TDO2TDP1NPC1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230278997-A1 BICYCLO[1.1.1]PENTANE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION HOFFMANN-LA ROCHE INC. (US) 2023-09-07 US disclosed
EP-4161921-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF Anima Biotech Inc. (US) 2023-04-12 EP disclosed
WO-2022142731-A1 ANTIVIRAL COMPOUND AND PREPARATION METHOD THEREFOR 广东中科药物研究有限公司 2022-07-07 WO disclosed
EP-3184527-A1 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL Hydra Biosciences, Inc. (US) 2017-06-28 EP disclosed
EP-2170309-B1 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL HYDRA BIOSCIENCES INC (US) 2016-10-26 EP disclosed
CN-104781257-A Piperidinylpyrazolopyridine derivative DAIICHI SANKYO CO LTD 2015-07-15 CN disclosed
US-20130303521-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES HYDRA BIOSCIENCES, INC (US) 2013-11-14 US disclosed
US-20130165427-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES HYDRA BIOSCIENCES, INC. (US) 2013-06-27 US disclosed
US-20130059869-A1 METHODS AND COMPOSITIONS FOR TREATING DISORDERS HYDRA BIOSCIENCES, INC. 2013-03-07 US disclosed
US-20120108614-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES HYDRA BIOSCIENCES, INC. 2012-05-03 US disclosed
CN-102046622-A Novel macrocyclic inhibitors of hepatitis C virus replication INTERMUNE INC 2011-05-04 CN disclosed
CN-101304985-A Thiazole compounds and their use as PGDs2AntagonistsUse of ARGENTA DISCOVERY LTD (GB) 2008-11-12 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108614-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES ELANE, CASP3, MMP8 CYP19A1 2044/4885IDO1 3851/4885TDO2 3806/4885
US-20130303521-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES ELANE, CASP3, MMP8 CYP19A1 2044/4885IDO1 3851/4885TDO2 3806/4885
US-20130165427-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES ELANE, CASP3, MMP8 CYP19A1 2044/4885IDO1 3851/4885TDO2 3806/4885
US-20130059869-A1 METHODS AND COMPOSITIONS FOR TREATING DISORDERS TRPA1, TRPV1, TRPV3 CYP19A1 1202/4885IDO1 2838/4885TDO2 1850/4885
US-20230278997-A1 BICYCLO[1.1.1]PENTANE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION HAVCR2, CYP1B1, CYP7A1 CYP19A1 141/4885IDO1 243/4885TDO2 1415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.